Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/LABT/Operating income

Lakewood-Amedex Biotherapeutics Inc. (LABT) Operating income 2024–2025

Lakewood-Amedex Biotherapeutics Inc. (LABT) annual operating income history from SEC filings — each fiscal year as reported.

-$3.8MFY2025 · since FY2024: -$4.0M → -$3.8M
2425
Fiscal yearValueYoY
FY2025-$3.8M+6.3%
FY2024-$4.0M—

Source: SEC XBRL filings · For reference only · Not investment advice

More LABT financial trends

LABT RevenueLABT Net incomeLABT Net marginLABT Gross profitLABT Gross marginLABT Operating marginLABT Operating cash flowLABT Free cash flowLABT Capital expendituresLABT Return on equityLABT Stock buybacksLABT Dividends paidLABT Total assetsLABT Total liabilitiesLABT Shareholders’ equityLABT overview →